HESI THRIVE Research Grants

Funding Agency:
Health and Environmental Sciences Institute

THRIVE, a partner in the 2018 Biden Cancer Initiative, provides seed grants for nonclinical, clinical, and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. THRIVE also supports the development of approaches to avoid or lessen these effects.


Letters of Intent Due: Dec. 31, 2020

Agency Website

Areas of Interest

THRIVE is interested in research that will advance our:
• Fundamental understanding of cancer drug or therapy-related toxicity;
• Ability to identify and translate critical biomarkers of toxicity;
• Models (in vitro, in vivo, in silico) of pediatric or adult drug exposure that predict early or impending toxicities;
• Understanding the role of protective co-therapies or modified exposure protocols on the onset of therapy-induced damage; and
• Identification of novel protective therapies or dosing strategies.

Eligibility Requirements

• PI’s must hold and MD, PhD, DVM or equivalent degree. Candidates for these degrees along with their PI may apply.
• Candidates must have the ability to conduct independent research and have published in peer-reviewed journals.



Amount Description

• Range of $20,000 - $50,000 for up to 24 months
• Upon agreement to THRIVE award terms, THRIVE will disburse 75% of funds with the remaining provided upon completion of the study milestones.

Funding Type



Grad/Prof Students
Medical Fellow/Resident


Medical - Clinical Science
Medical - Translational

External Deadline

December 31, 2020